Patents by Inventor Catherine Castan
Catherine Castan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10092511Abstract: The invention relates to a pharmaceutical composition comprising a plurality of controlled-release coated microparticles each comprising a floating core, on the surface of which is deposited a layer containing at least one active principle, said layer being covered with a controlled-release coating, characterized by the fact that said floating core is composed of cellulose acetate phthalate and has an apparent density of less than or equal to 0.6 g/mL and said coated microparticles have a density of less than or equal to 0.7 g/mL.Type: GrantFiled: July 1, 2016Date of Patent: October 9, 2018Assignee: FLAMEL IRELAND LIMITEDInventors: Catherine Castan, Philippe Caisse
-
Patent number: 10004693Abstract: The invention relates to liquid pharmaceutical formulations for oral administration with the modified release of active principle(s), excluding amoxicillin, said formulations consisting of suspensions of coated particles of active principles (microcapsules). According to the invention, the microcapsules constituting the disperse phase of the suspension are designed to allow the modified release of the active principle(s) according to a profile that does not change during the storage of the liquid suspension. To do this the inventors propose the selection of a specific coating composition for the microcapsules which consists of at least four components that allow these microcapsules to be stored in water without modifying their properties of modified release of the active principle, this liquid phase furthermore being saturated with active principle(s).Type: GrantFiled: January 26, 2011Date of Patent: June 26, 2018Assignee: Flamel Ireland LimitedInventors: Catherine Castan, Florence Guimberteau, Rémi Meyrueix
-
Patent number: 9814684Abstract: The invention relates to liquid pharmaceutical formulations for oral administration with the modified release of active principle(s), excluding amoxicillin, said formulations consisting of suspensions of coated particles of active principles (microcapsules). According to the invention, the microcapsules constituting the disperse phase of the suspension are designed to allow the modified release of the active principle(s) according to a profile that does not change during the storage of the liquid suspension. To do this the inventors propose the selection of a specific coating composition for the microcapsules which consists of at least four components that allow these microcapsules to be stored in water without modifying their properties of modified release of the active principle, this liquid phase furthermore being saturated with active principle(s).Type: GrantFiled: September 9, 2015Date of Patent: November 14, 2017Assignee: FLAMEL IRELAND LIMITEDInventors: Catherine Castan, Florence Guimberteau, Rémi Meyrueix
-
Publication number: 20170281558Abstract: The invention relates to liquid pharmaceutical formulations for oral administration with the modified release of active principle(s), excluding amoxicillin, said formulations consisting of suspensions of coated particles of active principles (microcapsules). According to the invention, the microcapsules constituting the disperse phase of the suspension are designed to allow the modified release of the active principle(s) according to a profile that does not change during the storage of the liquid suspension. To do this the inventors propose the selection of a specific coating composition for the microcapsules which consists of at least four components that allow these microcapsules to be stored in water without modifying their properties of modified release of the active principle, this liquid phase furthermore being saturated with active principle(s).Type: ApplicationFiled: June 16, 2017Publication date: October 5, 2017Inventors: Catherine Castan, Florence Guimberteau, Rémi Meyrueix
-
Patent number: 9561179Abstract: The invention relates to a pharmaceutical composition comprising a plurality of controlled-release coated microparticles each comprising a floating core, on the surface of which is deposited a layer containing at least one active principle, said layer being covered with a controlled-release coating, characterized by the fact that said floating core is composed of cellulose acetate phthalate and has an apparent density of less than or equal to 0.6 g/mL and said coated microparticles have a density of less than or equal to 0.7 g/mL.Type: GrantFiled: May 28, 2010Date of Patent: February 7, 2017Assignee: FLAMEL IRELAND LIMITEDInventors: Catherine Castan, Philippe Caisse
-
Publication number: 20160310420Abstract: The invention relates to a pharmaceutical composition comprising a plurality of controlled-release coated microparticles each comprising a floating core, on the surface of which is deposited a layer containing at least one active principle, said layer being covered with a controlled-release coating, characterized by the fact that said floating core is composed of cellulose acetate phthalate and has an apparent density of less than or equal to 0.6 g/mL and said coated microparticles have a density of less than or equal to 0.7 g/mL.Type: ApplicationFiled: July 1, 2016Publication date: October 27, 2016Applicant: FLAMEL IRELAND LIMITEDInventors: Catherine Castan, Philippe Caisse
-
Publication number: 20150374636Abstract: The invention relates to liquid pharmaceutical formulations for oral administration with the modified release of active principle(s), excluding amoxicillin, said formulations consisting of suspensions of coated particles of active principles (microcapsules). According to the invention, the microcapsules constituting the disperse phase of the suspension are designed to allow the modified release of the active principle(s) according to a profile that does not change during the storage of the liquid suspension. To do this the inventors propose the selection of a specific coating composition for the microcapsules which consists of at least four components that allow these microcapsules to be stored in water without modifying their properties of modified release of the active principle, this liquid phase furthermore being saturated with active principle(s).Type: ApplicationFiled: September 9, 2015Publication date: December 31, 2015Inventors: Catherine Castan, Florence Guimberteau, Rémi Meyrueix
-
Publication number: 20150374635Abstract: The invention relates to liquid pharmaceutical formulations for oral administration with the modified release of active principle(s), excluding amoxicillin, said formulations consisting of suspensions of coated particles of active principles (microcapsules). According to the invention, the microcapsules constituting the disperse phase of the suspension are designed to allow the modified release of the active principle(s) according to a profile that does not change during the storage of the liquid suspension. To do this the inventors propose the selection of a specific coating composition for the microcapsules which consists of at least four components that allow these microcapsules to be stored in water without modifying their properties of modified release of the active principle, this liquid phase furthermore being saturated with active principle(s).Type: ApplicationFiled: September 9, 2015Publication date: December 31, 2015Inventors: Catherine Castan, Florence Guimberteau, Rémi Meyrueix
-
Publication number: 20150328168Abstract: An oral dosage form for the immediate release of at least one active compound, comprising coated particles consisting of a non-monocrystalline core containing said active compound and coated with at least one coating layer, said coating layer comprising (A) at least 15% by weight of water-insoluble polymer and (B) at least 40% by weight of polymer soluble in a 0.1N hydrochloric acid solution, the weight ratio polymer B/polymer A being comprised between 85/15 and 50/50, said coating layer representing at least 30% by weight of the total weight of said coated particles.Type: ApplicationFiled: December 12, 2013Publication date: November 19, 2015Applicant: Flamel Ireland LimitedInventors: Anne-Sophie DAVIAUD-VENET, Catherine CASTAN
-
Patent number: 8821935Abstract: The present invention is directed to microcapsules for reliably modified release and adapted to industrial reproduction of an active principle hardly water-soluble, other than anti-hyperglycemia agents. Each of said microcapsules comprises a core of hardly soluble active principle and a coating film applied on the core. Their mean diameter is less than 1000 microns. The coating film contains a film-forming polymer (PI) insoluble in gastrointestinal tract fluids, a water-soluble polymer (P2), a plasticizer (PL), and optionally a lubricating surfactant (TA). Said coating film represents at least 4% p/p of dry matter of their total weight, and its components P1, P2, PL satisfy the following characteristics: dry weight mass fraction of PI relative to the total coating weight ranging between 40 and 90%; dry matter weight fraction of PL/P1+P2 ranging between 15 and 60%; dry matter weight fraction of PL/P1+P2 ranging between 1 and 30%.Type: GrantFiled: October 20, 2006Date of Patent: September 2, 2014Assignee: Flamel TechnologiesInventors: Florence Guimberteau, Catherine Castan, Rémi Meyruiex, Gérard Soula
-
Patent number: 8734850Abstract: The field of the invention is that of oral pharmaceutical medicinal products or compositions, more particularly of the type of those comprising one or more active principles. The aim of the invention is to provide an improved oral medicinal product that can be administered in one or more daily doses, with modified release of active principle (in particular an active principle), for improving the prophylactic and therapeutic efficacy of such a medicinal product. This aim is achieved by means of the multimicrocapsular oral pharmaceutical form according to the invention in which the release of the AP is controlled by means of a double mechanism of triggering the release: “time triggering” and “pH triggering”. This medicinal product comprises microcapsules with modified release of active principle, each containing a core comprising the active principle and one or more swelling agents, and at least one coating making possible the modified release of the active principle.Type: GrantFiled: November 24, 2004Date of Patent: May 27, 2014Assignee: Flamel TechnologiesInventors: Catherine Castan, Florence Guimberteau, Remi Meyrueix, Gerard Soula
-
Patent number: 8652523Abstract: The invention concerns microcapsules with prolonged release of active principles with low solubility, consisting of a core containing the active principle and coated with a polymer layer which controls the release of the active principle. The aim is that said oral microcapsules containing hardly soluble active principles, should have a coating film of sufficient thickness to ensure controlled permeability and should be adapted to industrial reproduction. This is achieved by the inventive microcapsules of mean diameter less than 1000 microns, and whereof the coating film contains a film-forming polymer (P1) insoluble in gastrointestinal tract fluids, a water-soluble polymer (P2), a plasticizer (PL), and optionally a lubricating surfactant (TA).Type: GrantFiled: July 28, 2003Date of Patent: February 18, 2014Assignee: Flamel TechnologiesInventors: Florence Guimberteau, Catherine Castan, Rémi Meyrueix
-
Patent number: 8197850Abstract: The invention concerns an oral galenic form for prolonged release of anti-hyperglycaemic (metformin) active principles. Said medicine enables to obtain an efficient therapeutic protection over 24 hours by overcoming the problems of bypass of the absorption window and the massive localised release of active principles. Therefor, said medicine comprises several thousand anti-hyperglycaemic (metformin) microcapsules each consisting of a core comprising at least an anti-hyperglycaemic agent and of a coating film applied on the core and enabling the prolonged release in vivo of the anti-hyperglycaemic agent. Said microcapsules have a grain size distribution ranging between 50 and 100 microns. The reproducibility of the transit kinetics and hence of bioavailability are very high. There results for the patient a lesser risk of hyperglycaemic or hypoglycaemic. The invention also concerns the preparation of said medicine and the use of a plurality of said microcapsules for making an anti-hyperglycaemic medicine.Type: GrantFiled: November 19, 2001Date of Patent: June 12, 2012Assignee: Flamel TechnologiesInventors: Catherine Castan, Remi Meyrueix, Gerard Soula
-
Patent number: 8101209Abstract: The invention relates to a microparticulate system for the delayed and controlled release of active principles (AP) whose absorption window in vivo is essentially limited to the upper parts of the gastrointestinal tract, this system being intended for oral administration. The object of the invention is to provide a system ensuring that the AP is released with certainty by means of a dual mechanism of “time-dependent” and “pH-dependent” release. To achieve this object, the invention proposes a multimicrocapsular oral galenical form which is designed so as to guarantee therapeutic efficacy, and in which the release of the AP is governed by a dual release triggering mechanism that is “time-triggering” and “pH-triggering”. This system comprises of microcapsules (200 to 600 ?m) comprising a core of AP coated with a film (maximum 40% by weight) comprising a hydrophilic polymer A (Eudragit® L) and a hydrophobic compound B (vegetable wax, melting point=40-90° C.), B/A being between 0.2 and 1.5.Type: GrantFiled: April 19, 2004Date of Patent: January 24, 2012Assignee: Flamel TechnologiesInventors: Valérie Legrand, Catherine Castan, Rémi Meyrueix, Gérard Soula
-
Publication number: 20110129539Abstract: The invention concerns liquid pharmaceutical formulations, for oral delivery, with modified release of amoxicillin and consisting of suspensions of coated particles of amoxicillin (microcapsules). The microcapsules constituting the dispersed phase of the suspension are designed, according to the invention, to enable modified release of amoxicillin, in accordance with a profile which remains unaltered during the shelf life of the liquid suspension. Therefor, the invention consists in selecting a coating composition specific to the microcapsules consisting of at least four components enabling preservation of said microcapsules in water without altering their properties of modified release of amoxicillin, said liquid phase being furthermore saturated with amoxicillin.Type: ApplicationFiled: February 10, 2011Publication date: June 2, 2011Applicant: Flamel TechnologiesInventors: Catherine Castan, Florence Guimberteau, Rémi Meyrueix
-
Publication number: 20110117205Abstract: The invention relates to liquid pharmaceutical formulations for oral administration with the modified release of active principle(s), excluding amoxicillin, said formulations consisting of suspensions of coated particles of active principles (microcapsules). According to the invention, the microcapsules constituting the disperse phase of the suspension are designed to allow the modified release of the active principle(s) according to a profile that does not change during the storage of the liquid suspension. To do this the inventors propose the selection of a specific coating composition for the microcapsules which consists of at least four components that allow these microcapsules to be stored in water without modifying their properties of modified release of the active principle, this liquid phase furthermore being saturated with active principle(s).Type: ApplicationFiled: January 26, 2011Publication date: May 19, 2011Applicant: Flamel TechnologiesInventors: Catherine Castan, Florence Guimberteau, Rémi Meyrueix
-
Publication number: 20110091537Abstract: The present invention relates to a solid oral pharmaceutical form, with modified release of at least one active ingredient, containing at least microparticles containing said active ingredient and at least one viscosifying agent in a form isolated from said microparticles of active ingredient, characterized in that said microparticles possess an average diameter ranging from 100 to 600 ?m, and are formed by a core containing at least said active ingredient and coated with at least one coating layer, said core being formed by a support particle covered by a layer comprising at least said active ingredient, said coating layer being formed by a material composed of at least 25 to 70% by weight relative to the total weight of said coating, of at least one polymer A insoluble in water, 30 to 75% by weight relative to the total weight of said coating, of at least one polymer B insoluble in water below pH 5 and soluble in water above pH 7, and 0 to 25% by weight relative to the total weight of said coating, of atType: ApplicationFiled: October 15, 2010Publication date: April 21, 2011Applicant: Flamel TechnologiesInventors: Catherine Castan, Anne-Sophie DAVIAUD-VENET
-
Patent number: 7910133Abstract: The invention relates to liquid pharmaceutical formulations for oral administration with the modified release of amoxicillin, said formulations consisting of suspensions of coated particles of amoxicillin (microcapsules). According to the invention, the microcapsules constituting the disperse phase of the suspension are designed to allow the modified release of the amoxicillin according to a profile that does not change during the storage of the liquid suspension. To do this the inventors propose the selection of a specific coating composition for the microcapsules which consists of at least four components that allow these microcapsules to be stored in water without modifying their properties of modified release of the amoxicillin, this liquid phase furthermore being saturated with amoxicillin.Type: GrantFiled: April 7, 2003Date of Patent: March 22, 2011Assignee: Flamel TechnologiesInventors: Catherine Castan, Florence Guimberteau, Rémi Meyrueix
-
Patent number: 7906145Abstract: The invention concerns liquid pharmaceutical formulations, for oral delivery, with modified release of active principle(s) excluding amoxicillin and consisting of suspensions of coated particles of active principles (microcapsules). The microcapsules constituting the dispersed phase of the suspension are designed, according to the invention, to enable modified release of the active principle(s), in accordance with a profile which remains unaltered during the shelf life of the liquid suspension. Therefor, the invention consists in selecting a coating composition specific to the microcapsules consisting of at least four components enabling preservation of said microcapsules in water without altering their properties of modified release of the active principle, said liquid phase being furthermore saturated with active principle(s).Type: GrantFiled: April 7, 2003Date of Patent: March 15, 2011Assignee: Flamel TechnologiesInventors: Catherine Castan, Florence Guimberteau, Rémi Meyrueix
-
Patent number: RE47084Abstract: The field of the invention is that of oral pharmaceutical medicinal products or compositions, more particularly of the type of those comprising one or more active principles. The aim of the invention is to provide an improved oral medicinal product that can be administered in one or more daily doses, with modified release of active principle (in particular an active principle), for improving the prophylactic and therapeutic efficacy of such a medicinal product. This aim is achieved by means of the multimicrocapsular oral pharmaceutical form according to the invention in which the release of the AP is controlled by means of a double mechanism of triggering the release: “time triggering” and “pH triggering”. This medicinal product comprises microcapsules with modified release of active principle, each containing a core comprising the active principle and one or more swelling agents, and at least one coating making possible the modified release of the active principle.Type: GrantFiled: May 27, 2016Date of Patent: October 16, 2018Assignee: FLAMEL IRELAND LIMITEDInventors: Catherine Castan, Florence Guimberteau, Remi Meyrueix, Gerard Soula